Female-фактор в формировании желчнокаменной болезни

1. Шаталов А.Д., Хацко В.В., Дудин А.М., Мамисашвили З.С., Страшко Е.Н. Современные представления об этиологии и патогенезе желчнокаменной болезни. Вестник гигиены и эпидемиологии. 2022;26(4):416–422. (Shatalov AD, Khatsko VV, Dudin AM, Mamisashvili ZS, Strashko EN. Modern concepts of the etiology and pathogenesis of cholelithiasis. Vestnik gigieny i epidemiologii = Bulletin of Hygiene and Epidemiology. 2022;26(4):416–422 (In Russ.)). EDN: UAQZLS.

2. Вахрушев Я.М., Хохлачева Н.А. Желчнокаменная болезнь: эпидемиология, факторы риска, особенности клинического течения, профилактика. Архивъ внутренней медицины. 2016;6(3):30–35. (Vakhrushev YaM, Khokhlacheva NA. Gallstone disease: Epidemiology, risk factors, clinical course features, prevention. Arkhiv vnutrenney meditsiny = Archive of Internal Medicine. 2016;6(3):30–35 (In Russ.)).

EDN: VZTUIL. https://doi.org/10.20514/2226-6704-2016-6-3-30-35

3. Di Ciaula A, Wang DQ-H, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018;34(2):71–80.

PMID: 29283909. PMCID: PMC8118137. https://doi.org/10.1097/MOG.0000000000000423

4. Lammert F, Gurusamy K, Ko CW, Miquel J-F, Méndez-Sánchez N, Portincasa P et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.

PMID: 27121416. https://doi.org/10.1038/nrdp.2016.24

5. Штыгашева О.В., Агеева Е.С., Чмыхало С.В. Консерватизм и дивергенция в семиотике желчнокаменной болезни. Экспериментальная и клиническая гастроэнтерология. 2022;(8):63–69. (Shtygasheva OV, Ageeva ES, Chmykhalo SV. Conservatism and divergence in the semiotics of cholelithiasis. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2022;(8):63–69 (In Russ.)).

EDN: VMFRKX. https://doi.org/10.31146/1682-8658-ecg-204-8-63-69

6. Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for gallstone formation - a new data cohort study and a systematic review with meta-analysis. Scand J Gastroenterol. 2016;51(10):1239–48.

PMID: 27232657. https://doi.org/10.1080/00365521.2016.1182583

7. Суздалкина В.М., Свиркина К.В., Мокашева Е.Н., Мокашева Ек.Н. Гендерные особенности заболеваний желудочно-кишечного тракта. European Journal of Natural History. 2022;(2):65–70. (Suzdalkina VM, Svirkina KV, Mokasheva EN, Mokasheva EkN. Gender characteristics of gastrointestinal diseases. European Journal of Natural History. 2022;(2):65–70 (In Russ.)). EDN: ADAYSG.

8. Успенская Ю.Б., Шептулин А.А. Особенности патогенеза, диагностики и лечения желчнокаменной болезни при беременности. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):111–116. (Uspenskaya YuB, Sheptulin AA. Features of pathogenesis, diagnosis and treatment of cholelithiasis during pregnancy. Rossiiskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):111–116 (In Russ.)).

EDN: YKVHMZ. https://doi.org/10.22416/1382-4376-2017-27-2-111-116

9. Wang HH, Liu M, Clegg DJ, Portincasa P, Wang DQ-H. New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. Biochim Biophys Acta. 2009;1791(11):1037–47.

PMID: 19589396. PMCID: PMC2756670. https://doi.org/10.1016/j.bbalip.2009.06.006

10. Hay JE. Liver disease in pregnancy. Hepatology. 2008;47(3):1067–76.

PMID: 18265410. https://doi.org/10.1002/hep.22130

11. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346(5):340–52.

PMID: 11821512. https://doi.org/10.1056/NEJMra000471

12. Novacek G. Gender and gallstone disease. Wien Med Wochenschr. 2006;156(19–20):527–33.

PMID: 17103289. https://doi.org/10.1007/s10354-006-0346-x

13. DeLeon C, Wang DQ-H, Arnatt CK. G Protein-coupled estrogen receptor, GPER1, offers a novel target for the treatment ofdigestive diseases. Front Endocrinol (Lausanne). 2020;11:578536.

PMID: 33281743. PMCID: PMC7689683. https://doi.org/10.3389/fendo.2020.578536

14. Успенская Ю.Б. Современные возможности профилактики и лечения желчнокаменной болезни в период беременности. Фарматека. 2016;(12):20–28. (Uspenskaya YuB. Modern possibilities of prevention and treatment of cholelithiasis during pregnancy. Farmateka. 2016;(12):20–28 (In Russ.)). EDN: WWVQHB.

15. Balakrishnan G, Iqbal T, Uppinakudru G, Fernandes R, Bangera S, Dutt RA. The impact of lifestyle stressors, menstrual pattern, and cardiometabolic risk factors on young females with cholelithiasis. J Educ Health Promot. 2022;11:255.

PMID: 36325235. PMCID: PMC9621381. https://doi.org/10.4103/jehp.jehp_1767_21

16. Yuan S, Wang L, Sun J, Yu L, Zhou X, Yang J et al. Genetically predicted sex hormone levels and health outcomes: Phenome-wide Mendelian randomization investigation. Int J Epidemiol. 2022;51(6):1931–42.

PMID: 35218343. PMCID: PMC9749729. https://doi.org/10.1093/ije/dyac036

17. de Bari O, Wang TY, Liu M, Paik C-N, Portincasa P, Wang DQ-H. Cholesterol cholelithiasis in pregnant women: pathogenesis, prevention and treatment. Ann Hepatol. 2014;13(6):728–45. PMID: 25332259.

18. Ko CW, Beresford SAA, Schulte SJ, Matsumoto AM, Lee SP. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology. 2005;41(2):359–65.

PMID: 15660385. https://doi.org/10.1002/hep.20534

19. Грицева С.В., Денисов М.Ю. Изучение состояния органов билиарного тракта при невынашиваемости беременности. Материалы V Международного конгресса «Новые технологии в акушерстве, гинекологии, перинатологии и репродуктивной медицине». Новосибирск: Новосибирский национальный исследовательский государственный университет. 2021:121–128. (Gritseva SV, Denisov MYu. Study of the state of the biliary tract organs in case of miscarriage. Proceedings of the V International Congress “New Technologies in Obstetrics, Gynecology, Perinatology and Reproductive Medicine”. Novosibirsk: Novosibirsk National Research State University. 2021:121–128 (In Russ.)). EDN: NBVFPY.

20. Salari N, Hasheminezhad R, Heidarisharaf P, Khaleghi AA, Azizi AH, Shohaimi S, Mohammadi M. The global prevalence of gallstones in pregnancy: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol X. 2023;19:100237.

PMID: 37711873. PMCID: PMC10497987. https://doi.org/10.1016/j.eurox.2023.100237

21. Kilander C, Lagergren J, Konings P, Sadr-Azodi O, Brusselaers N. Menopausal hormone therapy and biliary tract cancer: A population-based matched cohort study in Sweden. Acta Oncol. 2019;58(3):290–95.

PMID: 30656997. https://doi.org/10.1080/0284186X.2018.1549367

22. Yuk J-S, Park JY. Menopausal hormone therapy increases the risk of gallstones: Health Insurance Database in South Korea (HISK)-based cohort study. PLoS One. 2023;18(12):e0294356.

PMID: 38048308. PMCID: PMC10695378. https://doi.org/10.1371/journal.pone.0294356

23. Dhiman RK, Chawla YK. Hormone replacement therapy and gallstone disease: A real association. Digestion. 2008;77(1):1–3.

PMID: 18212500. https://doi.org/10.1159/000113896

24. Jackson SS, Graubard BI, Gabbi C, Koshiol J. Association with menopausal hormone therapy and asymptomatic gallstones in US women in the third National Health and Nutrition Examination Study. Sci Rep. 2024;14(1):191.

PMID: 38168135. PMCID: PMC10761940. https://doi.org/10.1038/s41598-023-50509-2

25. Zhang G-Q, Chen J-L, Luo Y, Mathur MB, Anagnostis P, Nurmatov U et al. Menopausal hormone therapy and women’s health: An umbrella review. PLoS Med. 2021;18(8):e1003731.

PMID: 34339416. PMCID: PMC8366967. https://doi.org/10.1371/journal.pmed.1003731

26. Reshetnyak VI. Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol. 2012;4(2):18–34.

PMID: 22400083. PMCID: PMC3295849. https://doi.org/10.4254/wjh.v4.i2.18

27. Khan MK, Jalil MA, Khan MS. Oral contraceptives in gall stone diseases. Mymensingh Med J. 2007;16(2 Suppl):S40–45. PMID: 17917630.

28. Ali A, Perveen S, Khan I, Ahmed T, Nawaz A, Rab A. Symptomatic gallstones in young patients under the age of 30 years. Cureus. 2021;13(11):e19894.

PMID: 34976505. PMCID: PMC8712198. https://doi.org/10.7759/cureus.19894

29. Abu-Eshy SA, Mahfouz AA, Badr A, El Gamal MN, Al-Shehri MY, Salati MI, Rabie ME. Prevalence and risk factors of gallstone disease in a high altitude Saudi population. East Mediterr Health J. 2007;13(4):794–802. PMID: 17955761.

30. Wang S, Wang Y, Xu J, Chen Y. Is the oral contraceptive or hormone replacement therapy a risk factor for cholelithiasis: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(14):e6556.

PMID: 28383429. PMCID: PMC5411213. https://doi.org/10.1097/MD.0000000000006556

31. Harden K. Letter: Iatrogenic gall stones. Br Med J. 1976;1(6017):1074.

PMID: 1268565. PMCID: PMC1639856. https://doi.org/10.1136/bmj.1.6017.1074-c

32. Tirthani E, Said M, Neupane B, Quartuccio M. An unusual case of the “terrible triad” in a transgender woman. Cureus. 2021;13(8):e16869.

PMID: 34513444. PMCID: PMC8411995. https://doi.org/10.7759/cureus.16869

33. Tabernacki T, Loria M, Rhodes S, Pope R, Gupta S, Banik S, Mishra K. Gallbladder disease in transgender individuals: Associations with gender-affirming hormone therapy. Int J Transgend Health. 2023;25(4): 896–910.

PMID: 39465080. PMCID: PMC11500541. https://doi.org/10.1080/26895269.2023.2283532

34. Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015;125(3):605–10.

PMID: 25730222. PMCID: PMC4442681. https://doi.org/10.1097/AOG.0000000000000692

35. Littlefield A, Lenahan C. Cholelithiasis: Presentation and management. J Midwifery Womens Health. 2019;64(3):289–97.

PMID: 30908805. https://doi.org/10.1111/jmwh.12959

36. Клинические рекомендации. Желчнокаменная болезнь. Общероссийская общественная организация «Российское общество хирургов», Российская гастроэнтерологическая ассоциация, ассоциация «Эндоскопическое общество «РЭндО». Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 877_1. Доступ: https://cr.minzdrav.gov.ru/preview-cr/877_1 (дата обращения – 16.06.2025). (Clinical guidelines. Cholelithiasis. Russian Society of Surgeons, Russian Gastroenterological Association, Endoscopic Society “REnDO”. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 877_1. URL: https://cr.minzdrav.gov.ru/preview-cr/877_1 (date of access – 16.06.2025) (In Russ.)).

37. Di Ciaula A, Wang DQH, Wang HH, Bonfrate L, Portincasa P. Targets for current pharmacologic therapy in cholesterol gallstone disease. Gastroenterol Clin North Am. 2010;39(2):245–64,viii–ix.

PMID: 20478485. PMCID: PMC2915454. https://doi.org/10.1016/j.gtc.2010.02.005

38. Stein A, Hermoni D, Elis A, Konikoff FM. Effect of ezetimibe on the prevalence of cholelithiasis. World J Gastroenterol. 2012;18(40):5789–92.

PMID: 23155321. PMCID: PMC3484349. https://doi.org/10.3748/wjg.v18.i40.5789

39. Guarino MPL, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol. 2013;19(31):5029–34.

PMID: 23964136. PMCID: PMC3746374. https://doi.org/10.3748/wjg.v19.i31.5029